September 29, 2023
Philadelphia, PA -- Panorama Medicine (“Panorama”), a genomics and AI powered drug discovery company focusing on therapeutics for RNA splicing defects announced today that it has been awarded a Phase 1 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to further optimize its PAN™ AI discovery platform focusing on RNA expression and splicing.
Panorama has developed a groundbreaking platform that combines big data and genetic sequencing to identify the RNA sequence of splice events, a cause of up to 50% of genetic diseases. The NIH grant supports the efforts in modeling more complex disease-causing events and to demonstrate the capability of discovery of novel targets and modalities.
About Panorama Medicine
Panorama Medicine is a VC-backed startup founded by a multidisciplinary team of world-renowned computational and experimental RNA biologists. Panorama has created a drug discovery platform that integrates genomics, big data, computing, and artificial intelligence to develop therapeutic interventions for diseases caused by and related to RNA defects. The Panorama platform is end-to-end, encompassing data production and analysis through validation of discoveries and treatment modalities. Leveraging the strength of this platform, Panorama is advancing research in multiple targets that were unavailable to drug development.